Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Resminostat |
Synonyms | |
Therapy Description |
Resminostat (4SC-201) is a histone deacetylase inhibitor that induces chromatin remodeling, leading to growth inhibition and apoptosis in tumor cells (PMID: 20201941, PMID: 30198057, PMID: 30160566). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Resminostat | 4SC-201|BYK-408740|RAS-2410 | HDAC Inhibitor 45 | Resminostat (4SC-201) is a histone deacetylase inhibitor that induces chromatin remodeling, leading to growth inhibition and apoptosis in tumor cells (PMID: 20201941, PMID: 30198057, PMID: 30160566). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02953301 | Phase II | Resminostat | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN) | Completed | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CHE | BEL | AUT | 1 |